I

nvestment teams at healthcare insurance firms continue to encounter challenges, opportunities and ambiguities resulting from the low-interest-rate environment and balance sheet effects from the Affordable Care Act (ACA). This confluence of market and regulatory events has a meaningful impact on investment strategies across the $166 billion in cash and invested assets held by health insurers (Source: SNL, April 2015).

The impact from low rates is measurable, but to gain a deeper understanding of the ACA’s investment implications, PIMCO conducted a survey across a subset of U.S. health insurance companies during the fourth quarter of 2014. Despite differences in the ACA’s operational impact based on company size, location, product mix and other factors, two common themes emerged from the survey: Underwriting performance will be a larger factor in determining asset allocation changes, and liquidity and income will be emphasized to a greater degree.

At PIMCO, we believe the environment is ripe for health insurers to re-evaluate investment policies and positioning, with an emphasis on a broader opportunity set of asset classes and enhanced cash management to help portfolios increase contribution to profitability while carefully managing risk.

Underwriting performance will influence investment goals
As the ACA increasingly affects underwriting performance for health insurers, it will also become a larger driver of asset allocation decisions (see Figure 1). Changes in the size and characteristics of insured populations will influence cash flow, profitability and risk-based capital, which in turn will affect investment strategies.

In PIMCO’s survey, 95% of respondents expect premium volumes to increase as a result of the ACA. However, this growth may come at the expense of lower margins (see Figure 2).

On the asset side, margin pressure is driven by low reinvestment yields. On the underwriting side, margin pressure may result from an evolving insured mix/Medicaid expansion, increased competition (Source: Dept. of Health and Human Services), the “three Rs”and the Medical Loss Ratio rule. The “three Rs” are risk adjustment, risk corridors and reinsurance – risk-sharing programs put in place to mitigate the cost of adverse selection that may also incentivize aggressive pricing. Meanwhile, the Medical Loss Ratio rule imposes a minimum medical loss on health insurers, below which insurers are required to issue rebates to enrollees.

The investment implications are not clear-cut. While the expansion of new liabilities may elicit a more cautionary stance toward liquidity, the potential decline in operating margins may push insurers to look to their investment portfolio for higher income/returns.

Survey responses on intended asset allocation changes are consistent with this liquidity/return paradox, as insurers indicated larger increases in allocations to enhanced cash and, on the other end of the risk spectrum, emerging markets and private equity. Respondents also identified expected decreases in allocations to core bonds, largely driven by the low-rate environment (see Figure 3).

At PIMCO, we believe the Fed is moving closer to its first rate hike since 2006, which will be welcomed by portfolios struggling with record-low yields. The 2014 net yield on invested assets for health insurers stood at 2.06%, less than half of its 2006 level. However, even if rates begin to rise in 2015, they are unlikely to rise fast enough to provide a meaningful boost to yields. Expansion of global central bank balance sheets and cautious Fed policy will continue to support Treasury prices in the near term, and PIMCO expects the longer-term trajectory for the fed funds rate to be lower than in prior cycles due to structural factors including high debt levels and lower potential growth. In such an environment of lower expected returns and growth, alpha generation will become more important, and potentially a larger share of overall returns.

So how might insurers improve investment performance?

  • Look beyond domestic borders. As of year-end 2013, only 5% of health insurers’ bond exposure and 2% of their stock exposure represented foreign issuers. For investors willing to ease home bias, the divergence in global monetary policies has created attractive opportunities in global interest rates, credit, foreign exchange and equities.

  • Avoid external ratings bias. Below-investment-grade, or high yield (HY), securities tend to be avoided or minimized by insurers until they become upgraded into investment grade (IG). Similarly, many insurers exit investments downgraded below IG due to punitive capital charges, perceived impairment risk and/or optics. This creates a “buy high, sell low” dynamic.

    Since 2007, this ratings sensitivity, in the context of declining interest rates, has led health insurers to migrate down in quality within the investment grade spectrum (i.e., BBBs) to make up for lost yield (see Figure 4), which may not be optimal in light of tighter valuations. Insurers with comfortable liquidity/capital positions should consider utilizing the entire quality spectrum to find value, as select HY issuers with improving balance sheets may be a better investment than IG rated credits that are vulnerable to re-leveraging risks. An overreliance on external ratings provides a false sense of security.
  • Include a broader range of fixed income assets in your portfolio. The myriad of regulations and capital measures imposed on global banks has led to meaningfully stronger balance sheets, which typically benefit bondholders. Concurrently, many nonfinancial issuers have taken advantage of low yields to increase leverage and shareholder return. These balance sheet dynamics are not always appropriately priced across industries and capital structures, offering compelling opportunities for investors who can identify optimal points of risk and return along the debt/equity continuum.

    Many health insurance investment policies focus fixed income investments within a narrow range – choosing instead to take equity-like risk in their stock portfolios. Utilizing a mix of bank loans, preferreds, hybrids and other subordinated debt structures can help improve risk-adjusted yield/return.

  • Consider your “alternatives.” The effects of the ACA on balance sheets and profitability, in addition to low reinvestment yields, may force portfolios into a liquidity/return barbell, which suggests reserves not pledged toward increased operational needs may benefit from investment into more opportunistic (less liquid) strategies. This is especially true when valuations for bonds and public equities have continued to richen. Alternative investments, including unconstrained strategies and distressed funds, among others, can fill this gap – and indeed represent a growing area of interest among health insurers.

The bottom line is that health insurers operate in an environment of elevated uncertainty on both the liability side (fluidity of the ACA) and the asset side (central bank policies and associated volatility). This environment calls for having a well-diversified portfolio with flexible guidelines, reaching beyond domestic markets and crowded asset classes.

Enhanced cash and liquidity management
Working capital has always been a higher burden for healthcare insurers compared with property and casualty (P&C) and life insurance companies. This burden increased further for those that used operating cash, bank lines of credit and/or tapped the investment portfolio to cover ACA-related expenses.

Liquidity is further stressed due to the timing mismatch between medical claim payments and government reimbursements, which will increase for many due to the expansion of Medicaid. Additionally, the ACA’s competitive dynamics have accelerated mergers and acquisitions (M&A) and capital investments in complementary health products/services, both of which represent additional uses of cash. All of this, compounded by low interest rates, explains why our survey participants emphasized liquidity and income as growing investment priorities associated with the ACA (see Figure 5).

From a liquidity perspective, increased financial regulation post-2008 has led to reduced dealer balance sheets, generally increasing the cost of trading longer-dated debt. In addition, money market mutual fund reforms effective in 2016 alter the concept of “cash equivalents” by establishing floating net asset values on institutional prime and institutional municipal money market funds, and may even apply liquidity fees and gates on redemptions in more extreme scenarios. These operational costs of liquidity are exacerbated by economic costs (i.e., low policy rates, negative real rates) for income-sensitive investors such as health insurers.

To address the conflict between maintaining conservative liquidity buffers and enhancing income, we advocate insurers implement appropriate liquidity tiering among cash equivalent, core, core plus and other strategies. The magnitude of each tier should be scaled based on both the level and uncertainty of working capital requirements (see Figure 6).

In case large liquidity needs require sales from the investment portfolio, insurers should be aware of the risk profile of the residual assets, as portfolios could become out of balance in terms of credit and/or interest rate exposures. Using an overlay to hedge unintended risks may be a viable approach that can allow the general account to efficiently normalize positioning over time.

Re-evaluate investment policies and remain nimble
Five years since the ACA was signed into law, the fluidity of the regulation and ongoing political challenges ensure the only thing that’s certain about the ACA is further uncertainty. The broader investment implications have also been complicated by the Fed’s zero interest rate regime. For now, health insurers generally expect increased premium volumes and shifts in insured profiles, which call for an increased emphasis on liquidity and income.

Re-examining investment policies and tiering liquid assets can help health insurers’ investment portfolios maintain flexibility while potentially contributing more to the bottom line.

The Author

Chitrang K. Purani

Portfolio Manager, Financial Institutions

Georgi Popov

Product Strategist

Disclosures

Pacific Investment Management Company LLC, 650 Newport Center Drive, Newport Beach, CA 92660 is regulated by the United States Securities and Exchange Commission. | PIMCO Europe Ltd (Company No. 2604517), PIMCO Europe, Ltd Amsterdam Branch (Company No. 24319743), and PIMCO Europe Ltd- Italy (Company No. 07533910969) are authorised and regulated by the Financial Conduct Authority (25 The North Colonnade, Canary Wharf, London E14 5HS) in the UK. The Amsterdam and Italy Branches are additionally regulated by the AFM and CONSOB in accordance with Article 27 of the Italian Consolidated Financial Act, respectively. PIMCO Europe Ltd services and products are available only to professional clients as defined in the Financial Conduct Authority’s Handbook and are not available to individual investors, who should not rely on this communication. | PIMCO Deutschland GmbH(Company No. 192083, Seidlstr. 24-24a, 80335 Munich, Germany) is authorised and regulated by the German Federal Financial Supervisory Authority (BaFin) (Marie- Curie-Str. 24-28, 60439 Frankfurt am Main) in Germany in accordance with Section 32 of the German Banking Act (KWG). The services and products provided by PIMCO Deutschland GmbH are available only to professional clients as defined in Section 31a para. 2 German Securities Trading Act (WpHG). They are not available to individual investors, who should not rely on this communication. | PIMCO (Schweiz) GmbH (registered in Switzerland, Company No. CH-020.4.038.582-2), Brandschenkestrasse 41, 8002 Zurich, Switzerland, Tel: + 41 44 512 49 10. The services and products provided by PIMCO Switzerland GmbH are not available to individual investors, who should not rely on this communication but contact their financial adviser. | PIMCO Asia Pte Ltd (8 Marina View, #30-01, Asia Square Tower 1, Singapore 018960, Registration No. 199804652K) is regulated by the Monetary Authority of Singapore as a holder of a capital markets services licence and an exempt financial adviser. The asset management services and investment products are not available to persons where provision of such services and products is unauthorised. | PIMCO Asia Limited (Suite 2201, 22nd Floor, Two International Finance Centre, No. 8 Finance Street, Central, Hong Kong) is licensed by the Securities and Futures Commission for Types 1, 4 and 9 regulated activities under the Securities and Futures Ordinance. The asset management services and investment products are not available to persons where provision of such services and products is unauthorised. | PIMCO Australia Pty Ltd ABN 54 084 280 508, AFSL 246862 (PIMCO Australia) offers products and services to both wholesale and retail clients as defined in the Corporations Act 2001 (limited to general financial product advice in the case of retail clients). This communication is provided for general information only without taking into account the objectives, financial situation or needs of any particular investors. | PIMCO Japan Ltd (Toranomon Towers Office 18F, 4-1-28, Toranomon, Minato-ku, Tokyo, Japan 105-0001) Financial Instruments Business Registration Number is Director of Kanto Local Finance Bureau (Financial Instruments Firm) No.382. PIMCO Japan Ltd is a member of Japan Investment Advisers Association and The Investment Trusts Association, Japan. Investment management products and services offered by PIMCO Japan Ltd are offered only to persons within its respective jurisdiction, and are not available to persons where provision of such products or services is unauthorized. Valuations of assets will fluctuate based upon prices of securities and values of derivative transactions in the portfolio, market conditions, interest rates, and credit risk, among others. Investments in foreign currency denominated assets will be affected by foreign exchange rates. There is no guarantee that the principal amount of the investment will be preserved, or that a certain return will be realized; the investment could suffer a loss. All profits and losses incur to the investor. The amounts, maximum amounts and calculation methodologies of each type of fee and expense and their total amounts will vary depending on the investment strategy, the status of investment performance, period of management and outstanding balance of assets and thus such fees and expenses cannot be set forth herein. | PIMCO Canada Corp. (199 Bay Street, Suite 2050, Commerce Court Station, P.O. Box 363, Toronto, ON, M5L 1G2) services and products may only be available in certain provinces or territories of Canada and only through dealers authorized for that purpose. | PIMCO Latin America Edifício Internacional Rio Praia do Flamengo, 154 1° andar, Rio de Janeiro – RJ Brasil 22210-906.

All investments contain risk and may lose value. This material contains the opinions of the author but not necessarily those of PIMCO and such opinions are subject to change without notice. This material has been distributed for informational purposes only and should not be considered as investment advice or a recommendation of any particular security, strategy or investment product. Information contained herein has been obtained from sources believed to be reliable, but not guaranteed. No part of this material may be reproduced in any form, or referred to in any other publication, without express written permission. PIMCO and YOUR GLOBAL INVESTMENT AUTHORITY are trademarks or registered trademarks of Allianz Asset Management of America L.P. and Pacific Investment Management Company LLC, respectively, in the United States and throughout the world. ©2015, PIMCO.